Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Co.'s product candidate, lorundrostat, is a proprietary, orally administered aldosterone synthase inhibitor that it is developing for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve blood pressure (BP) of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic. The MLYS average annual return since 2023 is shown above.
The Average Annual Return on the MLYS average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MLYS average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MLYS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|